Measuring α4β2* nicotinic acetylcholine receptor density in vivo with [ 18 F]nifene PET in the nonhuman primate

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 11, 2013, Pages 1806-1814

  Hillmer, Ansel T ^a,b   Wooten, Dustin W ^a,b   Slesarev, Maxim S ^b   Ahlers, Elizabeth O ^b   Barnhart, Todd E ^a   Schneider, Mary L ^c   Mukherjee, Jogeshwar ^d   Christian, Bradley T ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F nifene; Bmax; KD; multiple injection; nicotinic acetylcholine receptor; PET

Indexed keywords

NICOTINIC RECEPTOR ALPHA4BETA2; NIFENE F 18; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL EVALUATION; COLD; COMPARTMENT MODEL; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; IN VIVO STUDY; LATERAL GENICULATE BODY; MALE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PRIORITY JOURNAL; RECEPTOR DENSITY; RHESUS MONKEY; SCATCHARD PLOT; SUBICULUM;

ANIMALS; BRAIN; FEMALE; FLUORINE RADIOISOTOPES; KINETICS; MACACA MULATTA; MALE; MODELS, BIOLOGICAL; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRIDINES; PYRROLES; RECEPTORS, NICOTINIC;

EID: 84887104283     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2013.136     Document Type: Article

References (38)

1. Perry EK, Lee MLW, Martin-Ruiz CM, Court JA, Volsen SG, Merrit J et al. Cholinergic activity in Autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry 2001; 158: 1058-1066. (Pubitemid 32623109)
2. Burghaus L, Schü tz U, Krempel U, Lindstrom J, Schrö der H. Loss of nicotinic acetylcholine receptor subunits a4 and a7 in the cerebral cortex of Parkinson patients. Parkinsonism Relat Dis 2003; 9: 243-246. (Pubitemid 36627688)
3. Hellströ m-Lindahl E, Court JA. Nicotinic acetylcholine receptors during prenatal development and brain pathology in human aging. Behav Brain Res 2000; 113: 159-168. (Pubitemid 30645553)
4. Saricicek A, Esterlis I, Maloney K, Mineur Y, Ruf B, Muralidharan A et al. Persistent b2-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am J Psychiatry 2012; 169: 851-859.
5. Cosgrove KP, Batis J, Bois F, Maciejewski PK, Esterlis I, Kloczynski T et al. b2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry 2009; 66: 666-676.
6. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al. Consensus comenclature for in vivo imaging of reversibly binding radioligands. J Cerebr Blood Flow Metab 2007; 27: 1533-1539. (Pubitemid 47301451)
7. Sihver W, Gillberg P, Svensson A, Nordberg A. Autoradiographic comparison of [3H](-)nicotine, [3H]cytisine, and [3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease. Neuroscience 1999; 94: 685-696.
8. Pimlott SL, Piggott M, Owens J, Greally E, Court JA, Jaros E et al. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[125I]-A-85380. Neuropsychopharmacology 2004; 29: 108-116. (Pubitemid 38068020)
9. Houghtling RA, Davila-Garcia MI, Kellar KJ. Characterization of (±)-[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. Mol Pharm 1995; 48: 280-287.
10. Sihver W, Gillberg P, Nordberg A. Laminar distribution of nicotinic receptor subtypes in human cerebral cortex as determined by [3H](-)nicotine, [3H]cytisine and [3H]epibatidine in vitro autoradiography. Neuroscience 1998; 85: 1121-1133.
11. Gallezot J-D, Bottlaender M, Delforge J, Valette H, Saba W, Dollé F et al. Quantification of cerebral nicotinic acetylcholine receptors by PET using 2-[18F]fluoro-A-85380 and the multiinjection approach. J Cerebr Blood Flow Metab 2008; 28: 172-189.
12. Pichika R, Easwaramoorthy B, Collins D, Christian BT, Shi B, Narayanan TK et al. Nicotinic a4b2 receptor imaging agents: part II. Synthesis and biological evaluation of 2-[18F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primate. Nucl Med Biol 2006; 33: 295-304.
13. Hillmer AT, Wooten DW, Slesarev MS, Ahlers EO, Barnhart TE, Murali D et al. PET imaging of a4b2 nicotinic acetylcholine receptors: quantitative analysis of 18F-nifene kinetics in the nonhuman primate. J Nucl Med 2012; 53: 1471-1480.
14. Hillmer AT, Wooten DW, Moirano JM, Slesarev M, Barnhart TE, Engle JW et al. Specific a4b2 nicotinic acetylcholine receptor binding of [F-18]nifene in the rhesus monkey. Synapse 2011; 65: 1309-1318.
15. Salinas C, Muzic RF, Ernsberger P, Saidel GM. Robust experiment design for estimating myocardial b adrenergic receptor concentration using PET. Med Phys 2007; 31: 151-165. (Pubitemid 46035237)
16. Muzic RF, Cornelius S. COMKAT: Compartment model kinetic analysis tool. J Nucl Med 2001; 42: 636-645. (Pubitemid 32298286)
17. Tai YC, Chatziioannou A, Siegel S, Young J, Newport D, Goble RN et al. Performance evaluation of the microPET P4: a PET system dedicated to animal imaging. Phys Med Biol 2001; 46: 1856-1862.
18. Feng D, Huang S-C, Wang X. Models for computer simulation studies of input functions for tracer kinetic modeling with positron emission tomography. Int J Biomed Comput 1993; 32: 95-110. (Pubitemid 23090835)
19. Christian BT, Vandehey NT, Floberg JM, Mistretta CA. Dynamic PET denoising with HYPR processing. J Nucl Med 2010; 51: 1147-1154.
20. Delforge J, Syrota A, Mazoyer BM. Identifiability analysis and parameter identification of an in vivo ligand-receptor model from PET data. IEEE Trans Bio Med Eng 1990; 37: 653-661. (Pubitemid 20293265)
21. Morris ED, Christian BT, Yoder KK, Muzic RF. Estimation of local receptor density Bmax and other parameters via multiple-injection PET experiments. In: Abelson JN, Simon MI (eds). Methods in Enzymology Vol 385. Academic Press: New York, 2004, pp 184-213. (Pubitemid 38656328)
22. Muzic RF, Christian BT. Evaluation of objective functions for estimation of kinetic parameters. Med Phys 2006; 33: 342-353. (Pubitemid 43183976)
23. Vandehey NT, Moirano JM, Converse AK, Holden JE, Mukherjee J, Murali D et al. High-affinity dopamine D2/D3 PET radioligands [18F]-fallypride and [11C]-FLB457: a comparison of kinetics in extrastriatial regions using a multiple-injection protocol. J Cerebr Blood Flow Metab 2010; 30: 994-1007.
24. Farde L, Eriksson L, Blomquist G, Halldin C. Kinetic analysis of ventral [11C]raclopride binding to D2-dopamine receptors studied by PET-a comparison to the equilibrium analysis. J Cerebr Blood Flow Metab 1989; 9: 696-708. (Pubitemid 19239491)
25. Holden JE, Jivan S, Ruth TJ, Doudet DJ. In vivo receptor assay with multiple ligand concentrations: an equilibrium approach. J Cerebr Blood Flow Metab 2002; 22: 1132-1141. (Pubitemid 35006806)
26. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cerebr Blood Flow Metab 1996; 16: 42-52.
27. Christian BT, Narayanan T, Shi B, Morris ED, Mantil J, Mukherjee J. Measuring the in vivo binding parameters of [18F]-fallypride in monkeys using a PET multiple-injection protocol. J Cerebr Blood Flow Metab 2004; 24: 309-322. (Pubitemid 38314587)
28. Wooten DW, Hillmer AT, Moirano JM, Tudorasacu D, Ahlers EO, Slesarev MS et al. 5-HT1A sex based differences in Bmax, in vivo KD, and BPND in the nonhuman primate. NeuroImage 2013; 77: 125-132.
29. Josserand V, Pelerin H, De Bruin B, Jego B, Kuhnast B, Hinnen F et al. Evaluation of drug penetration into the brain: a double study by in vivo imaging with positron emission tomography and using an in vitro model of the human blood-brain barrier. J Pharmacol Exp Ther 2006; 316: 79-86. (Pubitemid 41832583)
30. Dischino D, Welch MJ, Kilborun MR, Raichle ME. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med 1983; 24: 1030-1038. (Pubitemid 14206457)
31. Allen DD, Lockman PR, Roder KE, Dwoskin LP, Crooks PA. Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter. J Phramacol Exp Ther 2003; 304: 1268-1274. (Pubitemid 36254440)
32. Deuther-Conrad W, Patt JT, Lockman PR, Allen DD, Patt M, Schildan A et al. Norchloro-fluoro-homoepibatidine (NCFHEB)-a promising radioligand for neuroimaging nicotinic acetylcholine receptors with PET. Eur Neuropsychopharmacol 2008; 18: 222-229.
33. Hillmer AT, Wooten DW, Farhoud M, Barnhart TE, Mukherjee J, Christian BT. The effects of lobeline on a4b2 nicotinic acetylcholine receptor binding and uptake of [18F]nifene in rats. J Neurosci Methods 2013; 214: 163-169.
34. Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 2004; 74: 363-396. (Pubitemid 40092737)
35. Morris ED, Bonab AA, Alpert NM, Fischman AJ, Madras BK, Christian BT. Concentration of dopamine transporters: to Bmax or not to Bmax? Synapse 1999; 32: 136-140. (Pubitemid 29230143)
36. Brody AL, Mandelkern MA, London ED, Olmstead RE, Farahi J, Scheibal D et al. Cigarette smoking saturates brain a4b2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 2006; 63: 907-915. (Pubitemid 44192334)
37. Gallezot J-D, Bottlaender M, Gregoire M-C, Roumenov D, Deverre J-R, Coulon C et al. In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-[18F]-Fluoro-A-85380 and PET. J Nucl Med 2005; 46: 240-247. (Pubitemid 43073430)
38. Esterlis I, Cosgrove KP, Batis JC, Bois F, Stiklus SM, Perkins E et al. Quantification of smoking-induced occupancy of b2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding. J Nucl Med 2010; 51: 1226-1233.